Akebia Therapeutics Inc (AKBA):企業の財務・戦略的SWOT分析

◆英語タイトル:Akebia Therapeutics Inc (AKBA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH136059FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥68,400見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥102,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF-PH inhibitor, a regulator for the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions for the treatment of anemia due to chronic kidney disease (CKD). The company’s product pipeline includes AKB-5169, an oral treatment for inflammatory bowel disease. The company works in partnership with Otsuka Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, and Vifor Pharma Management Ltd for the development and commercialization of its pipeline products. The company has its operations in the US and Ireland. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Akebia Therapeutics Inc Key Recent Developments

Mar 25,2021: Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
Mar 02,2021: Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Feb 25,2021: Akebia reports fourth quarter and full-year 2020 financial results and provides business updates

This comprehensive SWOT profile of Akebia Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Akebia Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Akebia Therapeutics Inc – Key Information
Akebia Therapeutics Inc – Overview
Akebia Therapeutics Inc – Key Employees
Akebia Therapeutics Inc – Key Employee Biographies
Akebia Therapeutics Inc – Key Operational Heads
Akebia Therapeutics Inc – Major Products and Services
Akebia Therapeutics Inc – History
Akebia Therapeutics Inc – Company Statement
Akebia Therapeutics Inc – Locations And Subsidiaries
Akebia Therapeutics Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Akebia Therapeutics Inc – Business Description
Akebia Therapeutics Inc – Corporate Strategy
Akebia Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Akebia Therapeutics Inc – Strengths
Akebia Therapeutics Inc – Weaknesses
Akebia Therapeutics Inc – Opportunities
Akebia Therapeutics Inc – Threats
Akebia Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Akebia Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Akebia Therapeutics Inc, Key Information
Akebia Therapeutics Inc, Key Ratios
Akebia Therapeutics Inc, Share Data
Akebia Therapeutics Inc, Major Products and Services
Akebia Therapeutics Inc, History
Akebia Therapeutics Inc, Key Employees
Akebia Therapeutics Inc, Key Employee Biographies
Akebia Therapeutics Inc, Key Operational Heads
Akebia Therapeutics Inc, Other Locations
Akebia Therapeutics Inc, Subsidiaries
Akebia Therapeutics Inc, Key Competitors
Akebia Therapeutics Inc, SWOT Analysis
Akebia Therapeutics Inc, Ratios based on current share price
Akebia Therapeutics Inc, Annual Ratios
Akebia Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Akebia Therapeutics Inc (AKBA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Village Roadshow Ltd:企業の戦略・SWOT・財務情報
    Village Roadshow Ltd - Strategy, SWOT and Corporate Finance Report Summary Village Roadshow Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Kitoku Shinryo Co., Ltd.:企業の戦略・SWOT・財務情報
    Kitoku Shinryo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kitoku Shinryo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Xiangxue Pharmaceutical Co Ltd (300147):製薬・医療:M&Aディール及び事業提携情報
    Summary Xiangxue Pharmaceutical Co Ltd (XPH) is a pharmaceutical company that manufactures and distributes drugs and medicines. The company’s products include drugs, Chinese medicine pieces, medical instruments, health products and medicinal drinks, among others. It also provides healthcare suppleme …
  • CITIC Securities Company Limited:企業の戦略・SWOT・財務分析
    CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • National Gypsum Co:企業の戦略・SWOT・財務分析
    National Gypsum Co - Strategy, SWOT and Corporate Finance Report Summary National Gypsum Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • DSV AS (DSV):企業の財務・戦略的SWOT分析
    DSV AS (DSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • TBG Diagnostics Ltd (TDL):医療機器:M&Aディール及び事業提携情報
    Summary TBG Diagnostics Ltd (TBG Diagnostics), formerly Progen Pharmaceuticals Ltd, is a molecular diagnostics company that develops, manufactures and markets molecular diagnostics kits, instruments and services. The company’s major products include nucleic acid extraction kits, HLA SBT typing kits, …
  • J. Front Retailing Co Ltd
    J. Front Retailing Co Ltd - Strategy, SWOT and Corporate Finance Report Summary J. Front Retailing Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Tieto Corp (TIETO):企業の財務・戦略的SWOT分析
    Tieto Corp (TIETO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • 3P Biopharmaceuticals SL-製薬・医療分野:企業M&A・提携分析
    Summary 3P Biopharmaceuticals SL (3P), a subsidiary of Infarco SA is a biotechnology company that offers biological and cell therapy products. The company offers biologic services such as cell-banks, process development, GMP manufacturing and analytical QC services. Its cell therapy services compris …
  • Venus Remedies Ltd (VENUSREM)-製薬・医療分野:企業M&A・提携分析
    Summary Venus Remedies Ltd (Venus) is a pharmaceutical company that develops, manufactures and commercializes research, herbal and generic products. The company manufactures complex formulations for oncology injections, neurology, antiseptic, pain management, anti infectives, oncology lyophilized, l …
  • Diamyd Medical AB (DMYD B):企業の財務・戦略的SWOT分析
    Summary Diamyd Medical AB (Diamyd), formerly Diamyd Therapeutics AB is a drug development company that offers diabetes vaccine. The company's diabetes products include Diamyd, an antigen-based immunotherapy for the treatment of autoimmune diabetes. Its pipeline products include GAD, GABA, and other …
  • Wahl Clipper Corporation:企業の戦略・SWOT・財務情報
    Wahl Clipper Corporation - Strategy, SWOT and Corporate Finance Report Summary Wahl Clipper Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Pyxus International Inc:企業の戦略・SWOT・財務分析
    Pyxus International Inc - Strategy, SWOT and Corporate Finance Report Summary Pyxus International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Uni-President China Holdings Ltd
    Uni-President China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Uni-President China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • SunTech Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary SunTech Medical Inc (SunTech) is a medical device company that manufactures and markets clinical-grade non-invasive blood pressure monitoring products and technologies. The company provides products such as ambulatory blood pressure monitoring products, blood pressure w and vitals, blood pre …
  • Astrazeneca Pharma India Ltd (ASTRAZEN):製薬・医療:M&Aディール及び事業提携情報
    Summary AstraZeneca Pharma India Ltd (AstraZeneca), a subsidiary of AstraZeneca Plc, is a biopharmaceutical company that discovers, develops, and commercializes medicines. The company offers products in the therapeutic areas of cardiovascular and metabolic diseases, respiratory, maternal healthcare, …
  • Global Telecom Holding S.A.E. (GLTD):企業の財務・戦略的SWOT分析
    Global Telecom Holding S.A.E. (GLTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Pan American Silver Corp:企業の戦略・SWOT・財務情報
    Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report Summary Pan American Silver Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • VSE Corporation (VSEC):企業の財務・戦略的SWOT分析
    VSE Corporation (VSEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆